Abstract-Cytochrome P450-derived epoxyeicosatrienoic acids are potent vasodilators in preclinical models and are hydrolyzed by soluble epoxide hydrolase (EPHX2). Associations between the EPHX2 Lys55Arg and Arg287Gln polymorphisms and cardiovascular disease risk have been reported; however, their impact on vascular function in humans has not been investigated. In 265 volunteers (198 white, 67 black American), forearm blood flow was measured by strain-gauge venous occlusion plethysmography at baseline and in response to bradykinin, methacholine, and sodium nitroprusside. Forearm vascular resistance was calculated as mean arterial pressure/forearm blood flow. In white Americans, Lys55Arg genotype was associated with vasodilator response to bradykinin, such that forearm blood flow was significantly lower (Pϭ0.043) and forearm vascular resistance was significantly higher (Pϭ0.013) in Arg55 variant allele carriers compared to wild-type individuals. Significant associations were also observed with methacholine and sodium nitroprusside. In contrast, no relationship was observed in black Americans. In black Americans, Arg287Gln genotype was associated with vasodilator response to bradykinin. Although the difference in forearm blood flow did not reach statistical significance (Pϭ0.058), forearm vascular resistance was significantly lower (Pϭ0.037) in Gln287 variant allele carriers compared to wild-type individuals. Significant associations were also observed with methacholine and sodium nitroprusside. In white Americans, Gln287 variant allele carriers did not exhibit significantly higher forearm blood flow (Pϭ0.128) or lower forearm vascular resistance (Pϭ0.080). Genetic variation in EPHX2 is associated with forearm vasodilator responses in a bradykinin receptorand endothelium-independent manner, suggesting an important role for soluble epoxide hydrolase in the regulation of vascular function in humans. Key Words: Soluble epoxide hydrolase Ⅲ EPHX2 polymorphism Ⅲ bradykinin Ⅲ endothelium-derived factors C ytochrome P450 (CYP) epoxygenase enzymes from the CYP2J and CYP2C subfamilies catalyze the oxidative metabolism of arachidonic acid to epoxyeicosatrienoic acids (EETs). 1 EETs are synthesized in the endothelium and cause vasodilation in numerous vascular beds via activation of calcium-sensitive potassium channels (BK Ca ) and smooth muscle cell hyperpolarization. 2,3 Consequently, CYP-derived EETs are regarded as one of the primary endothelium-derived hyperpolarizing factors. 2 Soluble epoxide hydrolase (sEH) rapidly hydrolyzes EETs to less biologically active dihydroxyeicosatrienoic acid metabolites. 4 Pharmacological inhibition of sEH increases cellular and circulating EET levels, potentiates EET-mediated vasodilation, and lowers blood pressure in preclinical models. 4 -6 Importantly, sEH inhibitors are currently in clinical development for the treatment of hypertension.
C ytochrome P450 (CYP) epoxygenase enzymes from the CYP2J and CYP2C subfamilies catalyze the oxidative metabolism of arachidonic acid to epoxyeicosatrienoic acids (EETs). 1 EETs are synthesized in the endothelium and cause vasodilation in numerous vascular beds via activation of calcium-sensitive potassium channels (BK Ca ) and smooth muscle cell hyperpolarization. 2, 3 Consequently, CYP-derived EETs are regarded as one of the primary endothelium-derived hyperpolarizing factors. 2 Soluble epoxide hydrolase (sEH) rapidly hydrolyzes EETs to less biologically active dihydroxyeicosatrienoic acid metabolites. 4 Pharmacological inhibition of sEH increases cellular and circulating EET levels, potentiates EET-mediated vasodilation, and lowers blood pressure in preclinical models. 4 -6 Importantly, sEH inhibitors are currently in clinical development for the treatment of hypertension.
Associations between polymorphisms in the gene encoding sEH (EPHX2) and cardiovascular and cerebrovascular disease risk in humans have been reported recently. [7] [8] [9] [10] [11] [12] [13] Most notably, the nonsynonymous Arg287Gln and Lys55Arg polymorphisms exhibit lower and higher sEH metabolic activity in vitro, respectively. 14 -16 The Gln287 variant allele has been associated with a lower prevalence of ischemic stroke in a Chinese population, 8 although the presence and strength of this relationship has been inconsistent across studies and racial groups. 9, 10, 17 The Arg55 variant allele has been associated with significantly higher risk of developing coronary artery disease and ischemic stroke events in populations of European ancestry. 11, 12 Although multiple reports demonstrate presence of a significant relationship between genetic variation in EPHX2 and cardiovascular and cerebrovascular disease risk in humans, 8 -13 the role of sEH in the regulation of vascular function in humans remains poorly understood. Because of their effects on sEH metabolic function in vitro, we hypothesized that the Arg55 and Gln287 variant alleles, respectively, predispose individuals to higher and lower vascular resistance in vivo. Consequently, we characterized the relationship between genetic variation in EPHX2 and forearm vasodilator responses.
Methods
Please see http://hyper.ahajournals.org for an expanded description of the methods.
Subjects
DNA was extracted from 265 healthy adults who participated in studies that evaluated forearm vasodilator responses. 18, 19 All subjects gave written informed consent. The protocol was approved by the Vanderbilt University Institutional Review Board and conducted according to the Declaration of Helsinki.
Experimental Protocol
Forearm blood flow (FBF) was measured using strain-gauge venous occlusion plethysmography (D.E. Hokanson) at baseline and in response to incremental doses of bradykinin (100, 200, and 400 ng/min; Clinalfa AG), methacholine (3.2, 6.4, and 12.8 g/min; Pharmaceutical Compounding Center), and sodium nitroprusside (1.6, 3.2, and 6.4 g/min; Gensia Siccor Pharmaceuticals), as described previously. 18 -21 Forearm vascular resistance (FVR) was calculated as the ratio of mean arterial pressure/FBF.
Polymorphism Selection and Genotyping
In addition to the nonsynonymous Lys55Arg and Arg287Gln polymorphisms, eight polymorphisms in EPHX2 with Ͼ5% frequency and R 2 Ͻ 0.80 were also genotyped for haplotype construction (Table S1 ).
Statistical Analysis
Because of previously reported racial differences in forearm vasodilator responses, 18, 21 all analyses were stratified by race. Differences in FBF and FVR were determined using general linear model repeatedmeasures ANOVA in which the within-subject variable was vasoactive agent dose and the between-subject variables were genotype/haplotype group, cigarette smoking status (yes/no), and body mass index (quartile). 18, 19 A post hoc Scheffe's test was performed to identify betweengroup differences. Data are presented as least-squares meanϮSE unless otherwise indicated. To minimize the impact of the multiple statistical tests conducted, we estimated the false discovery rate (FDR) q-value for each comparison. 11, 22 Only q-values for statistically significant findings (PϽ0.05) are presented.
Results

EPHX2 Genotype and Subject Characteristics
Study subject characteristics and genotype distributions for the EPHX2 Lys55Arg and Arg287Gln polymorphisms are presented in Table 1 according to race. No significant differences in age, gender, cigarette smoking status, body mass index, or resting blood pressure were observed across either genotype in either racial group (Table S2) .
EPHX2 Genotype and Forearm Vasodilator Responses to Bradykinin
Bradykinin infusion increased FBF and decreased FVR in a dose-dependent fashion (Figures 1, 2 , and 3) but did not significantly affect mean arterial pressure or heart rate (PϭNS (Table S2) . In white Americans, vasodilator response to bradykinin was significantly associated with Lys55Arg genotype, such that FBF was significantly lower ( Figure 1A ) (Pϭ0.043, qϭ0.078) and FVR was significantly higher ( Figure 1C ) (Pϭ0.013, qϭ0.047) in Arg55 variant allele carriers (Lys/Arg or Arg/Arg) relative to wildtype (Lys/Lys) individuals. In contrast, genotype differences were not observed in black Americans ( Figure 1B and 1D) .
Resting FVR was significantly lower in black American Gln287 variant allele carriers (Arg/Gln or Gln/Gln) compared to wild-type (Arg/Arg) individuals (Pϭ0.040) (Table S2) . Although resting FBF also appeared to be higher in white and black Americans (Pϭ0.086 and Pϭ0.078, respectively) and FVR appeared to be lower in white Americans (Pϭ0.053), these differences were not statistically significant (Table S2) . Vasodilator response to bradykinin was associated with Arg287Gln genotype in black Americans. Although the difference in FBF did not reach statistical significance (Figure 2B ) (Pϭ0.058), FVR was significantly lower ( Figure 2D ) (Pϭ0.037, qϭ0.072) in Gln287 variant allele carriers relative to wild-type individuals. In white Americans, the observed differences in FBF (Figure 2A ) (Pϭ0.128) and FVR ( Figure  2C ) (Pϭ0.080) were less substantial than those observed in black Americans and were not statistically significant.
Inclusion of both Lys55Arg and Arg287Gln genotypes in the model did not alter the observed relationships between each individual polymorphism and FVR in either white (Lys55Arg Pϭ0.017, Arg287Gln Pϭ0.171) or black (Lys55Arg Pϭ0.731, Arg287Gln Pϭ0.037) Americans. An exploratory analysis evaluating the combination of both genotypes yielded consistent results ( Figure S1 ). baseline and in response to each agent in Gln287 variant allele carriers (Arg/Gln or Gln/Gln) relative to wild-type (Arg/Arg) individuals.
EPHX2 Haplotypes and Forearm Vasodilator Responses
Nine EPHX2 polymorphisms were included in haplotype construction, which identified six common haplotypes (Ͼ5%) in white American subjects ( Figure S2 ). Only one common haplotype was tagged by the Lys55Arg polymorphism variant G allele, which had a frequency of 13.7%. No differences in either resting FBF (Pϭ0.471) or FVR (Pϭ0.301) were observed in subjects carrying the variant Arg55-tagged haplotype. Vasodilator response to bradykinin, however, was significantly associated with this haplotype, such that FBF was significantly lower ( Figure 3A ) (Pϭ0.016, qϭ0.053) and FVR was significantly higher ( Figure 3B ) (Pϭ0.004, qϭ0.039) in subjects carrying the Arg55-tagged haplotype. Similar results were observed with Arg55-tagged haplotypes constructed using the sliding-window approach ( Figure S3 ). In response to incremental doses of methacholine and sodium nitroprusside, respectively, FBF was significantly lower (Pϭ0.025, qϭ0.063; and Pϭ0.001, qϭ0.016) and FVR was significantly higher (Pϭ0.009, qϭ0.047; and Pϭ0.001, qϭ0.016) in subjects carrying the Arg55-tagged haplotype.
A distinct haplotype tagged by the Arg287Gln polymorphism variant A allele had a frequency of 11.1%. Although carriers of the Gln287-tagged haplotype appeared to exhibit higher resting FBF (Pϭ0.127) and lower FVR (Pϭ0.083), these differences were not statistically significant. Similar results were observed with Gln287-tagged haplotypes constructed using the sliding-window approach ( Figure S3 ). No statistically significant associations between the Gln287-tagged haplotype and vasodilator responses to 
Discussion
CYP epoxygenases catalyze endothelial EET biosynthesis. These potent vasodilators are rapidly hydrolyzed by sEH, and pharmacological inhibition of sEH potentiates the effect of EETs. 1, 2, 4 This study identified a significant association between functional genetic variants in EPHX2, the gene that encodes sEH, and vascular function in humans. Specifically, the Arg55 variant allele was associated with significantly lower FBF and higher FVR in response to vasodilators in white Americans, while the Gln287 variant allele was associated with higher FBF and lower FVR at baseline and in response to vasodilators in black Americans. Similar genotype-phenotype relationships were observed in response to bradykinin, methacholine, and sodium nitroprusside, suggesting that the mechanism underlying the functional link between sEH and forearm vascular responsiveness in humans is both bradykinin receptor and endothelium independent. Collectively, these data demonstrate a potentially important role for sEH in the regulation of vascular function in humans and offer important mechanistic insight into previously reported associations between the EPHX2 Lys55Arg and Arg287Gln polymorphisms and cardiovascular and cerebrovascular disease risk.
The nonsynonymous Lys55Arg polymorphism exhibits higher sEH metabolic activity in vitro 14, 15 and in vivo 11 and has been associated with higher risk of coronary artery disease and ischemic stroke events in individuals of European ancestry. 11, 12 Consistent with higher sEH metabolic activity and EET hydrolysis, white American carriers of the Arg55 variant allele exhibited lower vasodilation responses com- pared to wild-type individuals. Lower vasodilation responses were also observed in carriers of the Arg55-tagged haplotype, suggesting that Lys55Arg is the functional allele driving these associations. We cannot rule out, however, that Lys55Arg is simply a marker in linkage disequilibrium with the true causative locus. In contrast, there was no association between Lys55Arg genotype and either resting or agoniststimulated changes in FBF or FVR in black American subjects. Although the mechanism underlying the racial differences in this genotype-phenotype relationship is not known, these findings are consistent with the prior observation that Lys55Arg genotype was associated with sEH metabolic activity in vivo and cardiovascular disease risk in white, but not black, Americans enrolled in the Atherosclerosis Risk in Communities study. 11 Multiple studies have demonstrated that the Arg287Gln polymorphism exhibits significantly lower sEH metabolic activity and EET hydrolysis in vitro, 14 -16 although its functional impact on sEH metabolic activity in vivo remains unknown. Epidemiological studies provide inconsistent data regarding the presence and direction of a significant relationship between the Arg287Gln polymorphism and risk of cardiovascular and cerebrovascular events. 8 -13,17 Consistent with the vascular protective effects associated with sEH inhibition in preclinical models, 4 the Gln287 variant allele was recently associated with a significantly lower risk of ischemic stroke in a Chinese population. 8 In contrast, the Gln287 variant allele was associated with a higher prevalence and extent of coronary artery calcification in black Americans 9 and insulin resistance in Japanese type 2 diabetics. 23 Similarly, in contrast to the neuronal protective effects conferred by the Gln287 variant allele in vitro, 15 an association with significantly higher risk of ischemic stroke was reported in a white European population. 10 No association with coronary artery disease and ischemic stroke risk has been observed in other white or black American 11, 13 and European populations. 12, 17 Collectively, these conflicting data demonstrate that the functional relevance of the Arg287Gln polymorphism in humans remains unclear and requires further study.
Consistent with the hypothesis that decreased endogenous sEH metabolic activity enhances the vasodilator effects of EETs, Gln287 variant allele carriers demonstrated higher FBF and lower FVR under basal and agonist-stimulated conditions compared to wild-type individuals in the current investigation. These data are also consistent with the observation that administration of pharmacological inhibitors of sEH cause vasodilation in preclinical models and isolated human vessels. 4 -6 The observed relationship between the Arg287Gln polymorphism and vasodilator responses was more pronounced in black American subjects compared to the white American subjects studied. Although the current study was underpowered to investigate genotype-by-genotype interactions in each racial group, an interaction between the Lys55Arg and Arg287Gln polymorphisms appears unlikely to account for the observed racial differences.
The Lys55Arg and Arg287Gln polymorphisms were associated with altered vasodilation responses to both bradykinin and methacholine. These endothelium-dependent vasodilators cause vascular relaxation in part by stimulating the endothelial formation of EETs, which subsequently hyperpolarize vascular smooth muscle. 2 Somewhat unexpectedly, these functional variants in EPHX2 also affected the endotheliumindependent vasodilator response to sodium nitroprusside. Although it is well established that endothelial-derived EETs act as paracrine mediators of vasodilation, 2 EPHX2 deletion and pharmacological sEH inhibition also attenuate vascular remodeling in preclinical models by potentiating the antiproliferative and anti-inflammatory effects of EETs. 24, 25 Our findings suggest that chronic interindividual differences in EET exposure based on Lys55Arg and Arg287Gln genotype could contribute to physiological differences in forearm vascular responsiveness via an effect on vascular remodeling. An important limitation of our work, however, is the lack of functional data demonstrating that Arg55 and Gln287 variant allele carriers, respectively, exhibit higher and lower EET hydrolysis in vivo. Additional studies will be necessary to characterize the direct effects of exogenous EET administration and sEH inhibition on vasodilation and vascular remodeling in humans and to define the underlying mechanisms. Moreover, although in vitro studies have demonstrated that the Arg55 and Gln287 variant alleles elicit lower and higher sEH phosphatase activity, respectively, 26,27 the potential contribution of sEH phosphatase activity to the association between EPHX2 polymorphisms, vascular function, and cardiovascular and cerebrovascular risk remains unknown and requires further investigation. This study examined the vascular effects of EPHX2 polymorphisms in one of the largest cohorts that directly measured vasodilation responses to infused agonists. Nevertheless, the relatively small sample size represents a limitation since we may have been underpowered to detect an association, particularly in the black Americans studied. Moreover, because of the very low number of homozygous Arg55 and Gln287 carriers, we were only powered to characterize these relationships using a dominant genetic model of inheritance. In the bradykinin studies, there was excellent power to detect a 30% difference in FVR across the Lys55Arg (␤ϭ0.97) and Arg287Gln (␤ϭ0.94) genotype groups in the white American subset. The power to detect these differences in the black American subset was considerably less (Lys55Arg ␤ϭ0.67, Arg287Gln ␤ϭ0.52). We also made multiple comparisons, and there is a possibility of false-positive associations. To account for this possibility, we calculated an FDR q-value for each comparison. Although no gold-standard q-value threshold has been established to identify "true" associations, incorporation of this statistical approach into candidate gene association studies has become an increasingly recognized method to account for multiple comparisons and enhance confidence in observed associations. 28 Since all q-values were estimated to be Ͻ0.08, we have a higher level of confidence in our reported findings. Importantly, validation in a wellpowered, independent population will be ultimately necessary to confirm presence of a functional relationship between genetic variation in EPHX2 and vasodilator responses in humans.
Perspectives
CYP epoxygenases catalyze the biosynthesis of EETs, which are potent vasodilators that undergo rapid hydrolysis by sEH. Although associations between polymorphisms in EPHX2 and cardiovascular and cerebrovascular disease risk have been reported recently, their impact on vascular function has remained unknown. The current study demonstrates that genetic variation in EPHX2 is significantly associated with vasodilator responses in humans. Specifically, carriers of the increased function Arg55 and decreased function Gln287 variant alleles were predisposed to attenuated and enhanced forearm vasodilator responses, respectively. Collectively, these findings suggest that sEH has an important role in the regulation of vascular resistance and blood pressure in humans and offer important mechanistic insight into previously reported associations between the EPHX2 Lys55Arg and Arg287Gln polymorphisms and cardiovascular and cerebrovascular disease risk. Pharmacological inhibition of sEH is currently under clinical development as a novel therapeutic strategy for the treatment of hypertension. These findings may ultimately help identify specific subsets of the population that may be more (Arg55 carriers) or less (Gln287 carriers) likely to respond to the antihypertensive effects of sEH inhibitors. 
SUPPLEMENTAL METHODS
Subjects. DNA was extracted from 265 healthy adults (198 white Americans, 67 black Americans) who participated in studies that evaluated forearm vasodilator responses. 1,2 Subjects were classified as either white or black American if all four grandparents were self-defined as the same race. All subjects gave written informed consent and underwent a history, physical examination, laboratory screening, and electrocardiogram. Subjects with significant cardiovascular, renal, pulmonary, endocrine or hematological disease, or taking medications including angiotensin-converting enzyme inhibitors, were excluded. All subjects were within 30% of their ideal body weight. Pregnancy was excluded in women of childbearing potential by measurement of urine β-human chorionic gonadotropin. The protocol was approved by the Vanderbilt University Institutional Review Board and conducted according to the Declaration of Helsinki.
Experimental Protocol. Studies were performed in the morning, in a temperature-controlled room. Subjects were studied in the supine position and in the fasting state. A 20-gauge polyurethane catheter (Cook, Inc., Bloomington, IN) was inserted into the brachial artery of the nondominant arm, and an intravenous catheter was placed in the antecubital vein. Arterial catheter patency was maintained by infusion of 0.9% sodium chloride at a rate of 1 mL/min, and subjects were allowed to rest for 30 minutes before baseline measurements and between drug infusions. Heart rate and blood pressure were continuously monitored in the contralateral arm throughout the protocol using an automated blood pressure cuff (GE Medical Systems, Tampa, FL). Forearm blood flow (FBF) was measured using strain-gauge venous occlusion plethysmography (D.E. Hokanson, Bellevue, WA) at baseline and in response to incremental doses of the vasodilators bradykinin (100, 200, and 400 ng/min; Clinalfa AG, Läufelfingen, Switzerland), methacholine (3.2, 6.4, and 12.8 g/min; Pharmaceutical Compounding Center, Nashville, TN) and sodium nitroprusside (1.6, 3.2, and 6.4 g/min; Gensia Siccor Pharmaceuticals, Irvine, CA), as described previously. [1] [2] [3] [4] Subjects included in the current analysis were evaluated as part of several studies designed to assess different biochemical mechanisms that contribute to the vascular effects of bradykinin. [1] [2] [3] [4] Although not all subjects received all doses of all vasodilators, the protocols were standardized across studies to assure that the forearm blood flow measures were obtained in the same manner.
Bradykinin (100 and 200 ng/min) was infused in all 265 subjects to evoke endotheliumdependent vasodilation. The 400 ng/min dose was also administered in 223 subjects. Methacholine was infused in 190 subjects to evoke endothelium-dependent, but bradykinin receptor-independent, vasodilation. Sodium nitroprusside was infused in 248 subjects to evoke endothelium-independent vasodilation. The sequence of drug administration was randomized to avoid an order effect. Each drug dose was infused for 5 minutes, and FBF was measured during the last 2 minutes of each drug infusion protocol. FBF is presented as mL/100 mL of volume of tissue/minute. Forearm vascular resistance (FVR) was calculated as the ratio of mean arterial pressure/FBF and expressed as mmHg/mL/100 mL of volume of tissue/minute.
Polymorphism Selection and Genotyping. The focus of this investigation was the nonsynonymous Lys55Arg (rs41507953) and Arg287Gln (rs751141) polymorphisms in EPHX2, which are both common in individuals of European and African ancestry. 5, 6 In order to assess variation throughout the gene, eight additional polymorphisms in coding and noncoding regions (A) The distribution of white and black American subjects carrying both major alleles (WT / WT), the Arg55 variant allele only (Arg55 / WT), the Gln287 variant allele only (WT / Gln287) or both variant alleles (Arg55 / Gln287) are provided. No evidence of linkage disequilibrium between the Lys55Arg and Arg287Gln polymorphisms was observed in either white (r 2 =0.025) or black Americans (r 2 =0.029). Consequently, only 5 white and 4 black subjects carried both variant alleles (Arg55 / Gln287). Overall, this exploratory two polymorphism analysis is consistent with the individual polymorphism analyses in white and black Americans; such that, (1) Arg55 variant allele carriers exhibit higher FVR in the presence of bradykinin in white Americans, but not at baseline or in black Americans, and (2) Gln287 variant allele carriers exhibit lower FVR at baseline and in the presence of bradykinin in black Americans, and modestly lower FVR at baseline, but not in the presence of bradykinin, in white Americans.
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(A) Pairwise estimates of linkage disequilibrium (LD, r 2 =0-100) are plotted between each of the 9 EPHX2 polymorphisms included in haplotype construction. Polymorphisms are numbered according to their relative position on the gene (Table S1 ). Black squares indicate complete LD (r 2 =100), white squares indicate zero LD (r 2 =0), and increasing intensity of gray indicates increasing degrees of LD between each polymorphism.
(B) EPHX2 haplotypes and frequencies in white Americans. Bold and underlined nucleotides are the haplotype-tagging minor alleles. One common haplotype included, and was therefore tagged by, the Lys55Arg polymorphism variant G allele. This haplotype had a frequency of 13.7% and also included minor alleles at the rs4149243, rs13269963 and rs1126452 polymorphisms, all of which are in modest to strong LD with Lys55Arg (r 2 =0.64, 0.46 and 0.39, respectively) despite being at opposite ends of the gene and as much as 40-kb apart. A distinct haplotype was tagged by the Arg287Gln polymorphism variant A allele. This haplotype had a frequency of 11.1% and also included the rs13269963 and rs1126452 polymorphisms, which are in modest LD with Arg287Gln (r 2 =0.27 and 0.29, respectively) despite being approximately 25-kb apart. Haplotypes with <5% frequency were combined into a single group for analysis. , 200 ng/min)  G A G G G A C Figure S3 . EPHX2 sliding-window haplotypes and forearm vascular resistance in response to bradykinin in white Americans.
EPHX2 haplotypes were constructed using a sliding-window approach that included three consecutive markers in construction. Bold and underlined nucleotides are the haplotype-tagging minor alleles. Haplotypes tagged by the Arg55 and Gln287 variant alleles, or predicted to be 10 tagged based on the whole gene haplotype analysis, are identified. Associations between haplotype and FVR at baseline and in response to increasing doses of bradykinin were evaluated by one-way ANOVA and general linear model repeated-measures ANOVA, respectively. Only haplotypes with >5% frequency were considered in the analysis. The ANOVA P-values are provided. P-values <0.05 are identified in bold and italics.
Overall, this sliding-window haplotype analysis is consistent with both the whole gene haplotype and individual polymorphism analyses in white Americans; such that, (1) the Arg55-tagged haplotypes were significantly associated with vascular responsiveness to bradykinin, but not baseline FVR, and (2) the Gln287-tagged haplotypes demonstrated a trend toward an association with baseline FVR, but not vascular responsiveness to bradykinin.
